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Objectives The aim of this study was to test the noninferiority of eptifibatide relative to abciximab in patients with ST-
segment elevation myocardial infarction (STEMI) treated with primary percutaneous coronary intervention (PCI).
Background Glycoprotein IIb/IIIa inhibitors are recommended by international guidelines in patients with acute coronary syn-
dromes undergoing PCI. Abciximab is recommended with a higher level of evidence than eptifibatide in patients
with STEMI. No large, prospective, randomized trial comparing abciximab and eptifibatide has been published.
Methods All (n  11,479) STEMI patients in Sweden who underwent primary PCI and received either eptifibatide or abcix-
imab from 2004 to 2007 were derived from the SCAAR (Swedish Coronary Angiography and Angioplasty Regis-
try). The primary end point was death or myocardial infarction (MI) during 1-year follow-up, with adjustment for
baseline differences with a multivariate logistic regression analysis including propensity score. The pre-specified
noninferiority margin was set to 1.29.
Results The combined end point occurred in 353 of 2,355 patients (15.0%) treated with eptifibatide and in 1,432
of 9,124 patients (15.7%) treated with abciximab. The unadjusted odds ratio (OR) for eptifibatide versus
abciximab was 0.95 (95% confidence interval [CI]: 0.84 to 1.08). Multivariate adjustment (n  11,317)
confirmed noninferiority, with an OR of 0.94 (95% CI: 0.82 to 1.09). The adjusted secondary end points
of death and MI separately also showed noninferiority, with ORs of 0.99 (95% CI: 0.82 to 1.19) and 0.88
(95% CI: 0.73 to 1.05), respectively.
Conclusions This large registry study suggests that eptifibatide is noninferior to abciximab in patients with STEMI undergoing
primary PCI with respect to death or MI during 1 year, thereby supporting the use of either drug in clinical
practice. (J Am Coll Cardiol 2010;56:470–5) © 2010 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.10.093p
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Hlycoprotein (GP) IIb/IIIa inhibitors potently inhibit
latelet aggregation and reduce the incidence of ischemic
vents in patients undergoing percutaneous coronary inter-
entions (PCIs), especially in patients with acute coronary
yndromes (ACS) (1–4). Abciximab is recommended with
high level of evidence in both the European and American
uidelines as adjunctive treatment during PCI for high-risk
rom the *Department of Cardiology and †Uppsala Clinical Research Center,
ppsala University, Uppsala, Sweden; ‡Department of Cardiology, Sahlgrenska
niversity Hospital, Gothenburg, Sweden; and the §Department of Cardiology,
inkoping University Hospital, Linkoping, Sweden. Dr. James has received research
upport to institution from Eli Lilly, and has research cooperation with Eli Lilly
abciximab) and Schering-Plough (eptifibatide).t
Manuscript received September 18, 2009; revised manuscript received October 16,
009, accepted October 26, 2009.atients with ACS, including primary PCI in patients with
T-segment elevation myocardial infarction (STEMI) (5–
). Eptifibatide and tirofiban have less scientific documen-
ation but are approved for adjunctive medical therapy
See page 476
uring PCI in stable coronary disease, as well as in patients
ith ACS (2,4,7,8). Eptifibatide is not recommended for
rimary PCI by the European guidelines (5) and receives a
ower level of evidence compared with abciximab in the
atest updated American College of Cardiology/American
eart Association STEMI guidelines (6,9).
In 2004, 2 large Swedish university hospitals changedheir GP IIb/IIIa inhibitor therapy from abciximab to
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August 3, 2010:470–5 Eptifibatide Is Noninferior to Abciximab in Primary PCIptifibatide on all indications to reduce pharmacological
osts. An additional 7 hospitals (of 27 hospitals performing
CI) have been using both abciximab and eptifibatide (10).
he present study was designed to test a pre-specified
ypothesis that eptifibatide is noninferior to abciximab with
espect to death or myocardial infarction (MI) during 1 year
n patients with STEMI undergoing primary PCI.
ethods
ubjects and study design. The patient population was
erived from SCAAR (Swedish Coronary Angiography and
ngioplasty Registry), a registry with complete coverage of
ll hospitals performing coronary angiography and inter-
entions in Sweden. The registry is supported by Swedish
ealth Authorities and is independent of commercial
unding (10).
Between January 2004 and December 2007, a total of
5,542 procedures were performed in 15,120 patients with
TEMI as primary PCI. In this retrospective observational
tudy, only patients with primary PCI receiving adjunctive
herapy with either eptifibatide or abciximab were included
n  11,479) (10). Each patient was followed for 1 year and
as included in the study only once. In hospitals using both
ptifibatide and abciximab, the selection of the GP IIb/IIIa
nhibitor was at the operator’s discretion. Patients receiving
irofiban (n  463) were excluded as well as patients
ndergoing rescue PCI. Patients treated with adjunctive
ondaparinux (n  15) or bivalirudin (n  63) were not
xcluded. All episodes of PCI-related bleeding during the
ospital stay were to be reported in the SCAAR registry
10), but this assessment was not a part of the primary
bjective of the study.
The long-term follow-up was derived by merging the
CAAR database with the Swedish Cause of Death
egister and the Swedish National Patient Register
egarding reinfarction after hospital discharge (Interna-
ional Classification of Diseases-10th Revision codes I21
Clinical CharacteristicsTable 1 Clinical Characteristics
Variable
All Patients
(n  11,479
Age, yrs 11,479
Women 11,479
Diabetes 11,479
Hypertension 11,479
Hyperlipidemia 11,478
Congestive heart failure 11,479
Current smoker 11,476
Previous myocardial infarction 11,479
Previous PCI 11,465
Previous CABG 11,475
Previous stroke 11,479
Previous renal failure 11,479
Previous major bleeding 11,479Data are expressed as median (25th–75th percentile) or percent (frequency)
CABG  coronary artery bypass grafting; n  number of patients with nonnd I22). The study was ap-
roved by the local ethics com-
ittee at Uppsala University.
he study complied with the
eclaration of Helsinki.
tatistical analysis. The pri-
ary hypothesis was that eptifi-
atide would be noninferior to
bciximab with respect to the
rimary end point of death or MI
t 1 year. The pre-specified non-
nferiority margin was set to
.29, preserving 50% of the esti-
ated effect by abciximab by the
oint estimate of the odds ratio
OR) of abciximab versus placebo in patients with STEMI
11,12). The pre-specified secondary end points were death
nd MI separately during 1 year of follow-up.
Logistic regression with drug as a predictor was used to
btain the estimates of ORs and 95% confidence intervals
CIs). To compensate for pre-treatment differences, we
dded propensity score (13) as a predictor in a multivariate
ogistic regression. The individual propensity scores, defined
s the conditional probability of obtaining eptifibatide,
ased on all variables in Tables 1 and 2, were estimated
sing multivariate logistic regression. Age was dichoto-
ized (65 years vs. 65 years) before entering the model.
ondaparinux and bivalirudin were not used as individual
actors in the propensity score analysis.
esults
total of 11,479 patients with STEMI underwent primary
CI with adjunctive therapy of either eptifibatide (n 
,355) or abciximab (n 9,124). Baseline characteristics are
resented in Table 1, and ongoing or periprocedural med-
cations are listed in Table 2.
Abbreviations
and Acronyms
ACS  acute coronary
syndromes
CI  confidence interval
GP  glycoprotein
MI  myocardial infarction
OR  odds ratio
PCI  percutaneous
coronary intervention
STEMI  ST-segment
elevation myocardial
infarction
Abciximab
(n  9,124)
Eptifibatide
(n  2,355)
65 (57–74) 65 (57–74)
28.1% (2,568) 27.0% (636)
17.7% (1,616) 16.3% (385)
34.6% (3,157) 33.6% (791)
18.1% (1,647) 16.5% (389)
3.3% (300) 2.9% (69)
29.5% (2,688) 27.7% (652)
14.9% (1,355) 14.8% (349)
8.6% (782) 9.0% (211)
2.7% (242) 3.0% (71)
5.0% (458) 4.1% (97)
1.0% (88) 1.2% (28)
3.2% (291) 2.6% (62).
missing values; PCI  percutaneous coronary intervention).
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Eptifibatide Is Noninferior to Abciximab in Primary PCI August 3, 2010:470–5During the follow-up period, a total of 908 patients died,
f whom 179 (7.6%) were in the eptifibatide group and 729
8.0%) were among the abciximab-treated patients. The
otal number of MIs was 1,016, of which 197 (8.4%)
ccurred in the eptifibatide group and 819 (9.0%) in the
bciximab group. The combined end point of death or MI
uring 1 year occurred in 353 patients (15.0%) treated with
ptifibatide and 1,432 patients (15.7%) treated with abcix-
mab. The unadjusted OR for eptifibatide versus abciximab
as 0.95 (95% CI: 0.84 to 1.08) (Fig. 1). Multivariate
djustment (n  11,317) using logistic regression with
ropensity score adjusting for all variables in Tables 1 and 2
lso showed noninferiority for eptifibatide versus abciximab,
ith an OR of 0.94 (95% CI: 0.82 to 1.09) (Fig. 2).
The unadjusted OR for death during 1 year was 0.95
95% CI: 0.80 to 1.12), and in a multivariate logistic
egression including propensity scores, the OR was 0.99
95% CI: 0.82 to 1.19) on the basis of 11,317 subjects
Fig. 3). The unadjusted OR for MI alone during 1 year of
ollow-up was 0.93 (95% CI: 0.79 to 1.09), and the
ropensity score-adjusted OR was 0.88 (95% CI: 0.73 to
Interventional CharacteristicsTable 2 Interventional Characteristics
Variable
All P
(n 
Radial artery puncture 1
Ongoing or periprocedural treatment
Acetylsalicylic acid 1
Clopidogrel 1
Unfractionated heparin 1
Low–molecular weight heparin 1
Warfarin 1
Bare-metal stent 1
Drug-eluting stent 1
Number of stents implanted 1
0
1
2
3
4
5
6
7
Coronary pathology 1
Inconclusive
Atheromatosis/no significant stenosis
1-vessel disease (not left main)
2-vessel disease (not left main)
3-vessel disease (not left main)
Left main stenosis
Procedure year 1
2004
2005
2006
2007
Data are expressed as percent (frequency).
Abbreviations as in Table 1..05; n  11,317) (Fig. 4). (As a secondary safety end point, a total of 318 episodes of
n-hospital PCI-related bleeding in hospital were recorded,
f which 75 (3.2%) were in the eptifibatide cohort and 243
2.7%) in the abciximab cohort. The unadjusted OR was
.20 (95% CI: 0.92 to 1.56).
iscussion
his large registry study demonstrates that patients with
TEMI undergoing primary PCI with either eptifibatide or
bciximab as adjunctive therapy experienced the combined
nd point of death or MI during 1-year follow-up at compa-
able rates (15.0% vs. 15.7%). The pre-specified noninferiority
argin for eptifibatide versus abciximab was also met in a
ultivariate regression analysis adjusting for differences in
aseline characteristics and cointerventions including a propen-
ity score. Adjusted ORs for the individual end points of death
nd MI also indicated noninferiority.
Abciximab has been shown to reduce the composite end
oint of death, ischemia-driven revascularization, reinfarc-
ion, and stroke at 6 months after PCI in patients with ACS
ts
9)
Abciximab
(n  9,124)
Eptifibatide
(n  2,355)
11.0% (1,000) 29.0% (682)
94.7% (8,622) 96.9% (2,277)
84.7% (7,718) 93.6% (2,179)
69.7% (6,356) 92.8% (2,179)
32.0% (2,913) 11.2% (263)
1.2% (110) 0.4% (10)
67.6% (6,165) 85.3% (2,009)
25.4% (2,320) 9.1% (215)
7.0% (639) 5.6% (131)
63.8% (5,825) 54.0% (1,271)
21.7% (1,982) 27.3% (642)
5.6% (512) 9.0% (213)
1.4% (129) 3.0% (70)
0.4% (32) 0.8% (20)
0.0% (3) 0.1% (3)
0.0% (2) 0.2% (5)
1.3% (117) 0.2% (5)
0.4% (34) 0.3% (6)
49.3% (4,499) 44.5% (1,047)
27.1% (2,473) 30.4% (717)
17.5% (1,599) 20.0% (472)
4.4% (402) 4.6% (108)
20.9% (1,909) 9.5% (224)
23.2% (2,119) 30.1% (709)
27.8% (2,537) 29.4% (693)
28.0% (2,559) 31.0% (729)atien
11,47
1,473
1,459
1,438
1,466
1,465
1,349
1,477
1,477
1,479
1,479
1,4791). In patients with STEMI, the addition of abciximab has,
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August 3, 2010:470–5 Eptifibatide Is Noninferior to Abciximab in Primary PCIn a meta-analysis, proven a significant reduction of the
omposite end point of death and MI from 19.0% to 12.9%
t 1 year, with a remaining positive effect for abciximab after
years of follow-up (11). Abciximab is therefore recom-
ended with a high level of evidence in both the European
nd American guidelines for patients with ACS, including
rimary PCI in STEMI (5–9).
Eptifibatide has shown a significant reduction in ischemic
nd points in stable coronary disease as well as in death and
onfatal MI within 30 days in patients with ACS (2).
owever, a small study (n  400) investigating upstream
ptifibatide treatment versus placebo in patients with
TEMI showed no reduction in the combined end point of
eath, reinfarction, or recurrent severe ischemia at 30 days
14). In the latest European guidelines for the treatment of
on–ST-segment elevation ACS, eptifibatide has received a
lass IIa recommendation (7), but because of the weaker
cientific evidence for the treatment of patients with
TEMI, eptifibatide is not a generally recommended treat-
ent during primary PCI (5,6,9).
Direct comparative studies between the two different GP
Ib/IIIa inhibitors are sparse, and a large prospective com-
arison between eptifibatide and abciximab with clinical
utcomes has not yet been performed. A retrospective
egistry study in which 3,541 primary PCI-treated patients
ith STEMI received adjunctive GP IIb/IIIa inhibitors
Figure 1 Univariate Analysis of the Combined Primary
End Point of Death or Myocardial Infarction
Cumulative nonadjusted event rates of the primary combined end point of
death or myocardial infarction during 1 year of follow-up for patients who under-
went primary percutaneous coronary intervention with adjunctive therapy with
either eptifibatide (red dashed line) or abciximab (black solid line). The unad-
justed odds ratio for eptifibatide versus abciximab was 0.95 (95% confidence
interval: 0.84 to 1.08), thereby indicating noninferiority between the 2 treat-
ments. Numbers at risk are shown below the figure.emonstrated no difference in the in-hospital outcome ofeath or recurrent MI (15). In the EVA-AMI (Eptifi-
atide Versus Abciximab in Primary PCI for Acute
yocardial Infarction) trial, 429 patients with STEMI
ere randomized to either abciximab (n  203) or eptifi-
atide (n  226), with the primary end point of ST-
egment resolution 1 h after the intervention. Although
esigned to show noninferiority between eptifibatide and
bciximab, in fact eptifibatide showed superiority regarding
he primary end point (16). The EVA-AMI trial was later
ncluded in a meta-analysis of 6 randomized trials compar-
ng abciximab (n 1,082) with small-molecule GP IIb/IIIa
nhibitors (eptifibatide [n  226] or tirofiban [n  889]),
howing no significant differences in the primary end point
f 30-day mortality or reinfarction (17). Compared with the
VA-AMI study, our study enrolled a much larger number
f patients with STEMI and provided a longer follow-up of
ard end points, including mortality.
Patients undergoing coronary interventions today have to
higher extent been pretreated with oral dual-antiplatelet
herapy than in previously published studies evaluating GP
Ib/IIIa inhibitors (2,18). One might hypothesize that this
mportant difference could affect the outcome and render
ess ischemic events compared with the prior GP IIb/IIIa
tudies performed before clopidogrel was available. With
urrent high rates of clopidogrel treatment and future
linical use of more potent P2Y12 inhibitors such as prasug-
Figure 2
Propensity Score-Adjusted Cumulative Risk
for the Combined Primary End Point
of Death or Myocardial Infarction
Cumulative event rates, estimated at the mean propensity score, of death or
myocardial infarction during 1 year of follow-up for patients who underwent pri-
mary percutaneous coronary intervention and received either eptifibatide (red
dashed line) or abciximab (black solid line). The odds ratio of 0.94 (95% confi-
dence interval: 0.82 to 1.09) suggested noninferiority of eptifibatide, as the
pre-specified noninferiority margin of 1.29 for the primary end point was met.
Numbers at risk are shown below the figure.
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Eptifibatide Is Noninferior to Abciximab in Primary PCI August 3, 2010:470–5el (19) and ticagrelor (20), the role of the GP IIb/IIIa
nhibitors may be more difficult to assess.
tudy limitations. Inherent limitations to a nonrandom-
zed registry study need to be addressed. Despite appropri-
te statistical adjustments, unknown confounders may have
ffected the results. To limit a potential doctor’s selection
ias, we compared the 2 solely eptifibatide-using hospitals
ith 2 similar abciximab-using hospitals. This evaluation
howed similar background characteristics as well as results
or these 2 cohorts.
During the study period, both anticoagulant and oral
ntiplatelet treatment have partly changed. The lack of
nformation about the clopidogrel loading doses and the
uration of clopidogrel treatment makes it impossible to
elate the timing of events with discontinuation of dual-
ntiplatelet therapy.
A trend for higher bleeding rates in the eptifibatide
ohort was seen, but report rates are likely to differ between
ospitals, and unknown biases are likely not accounted for.
he bleeding assessment was not a part of the primary end
oint, and no firm conclusion is thus drawn from this result.
onclusions
his large-scale registry study suggests that eptifibatide is
oninferior to abciximab in patients undergoing primary
CI regarding the composite end point of death or MI
uring a 1-year follow-up period after propensity score
Figure 3 Adjusted Cumulative Risk Function
for Death as a Secondary End Point
Cumulative event rates of the secondary end point of death alone, estimated
at the mean propensity score, during 1 year of follow-up for patients who
underwent primary percutaneous coronary intervention with adjunctive eptifi-
batide (red dashed line) or abciximab (black solid line). The adjusted second-
ary end point of death showed noninferiority (odds ratio: 0.99; 95% confidence
interval 0.82 to 1.19). Numbers at risk are shown below the figure.ultivariate adjustments. In the absence of large head-to-
ead prospective randomized comparisons of hard end
oints between these 2 commonly used GP IIb/IIIa inhib-
tors, our study supports the clinical use of either drug in
atients with STEMI undergoing primary PCI.
eprint requests and correspondence: Dr. Axel Åkerblom, Uppsala
linical Research Center, Uppsala University, UCR/MTC, 751 85
ppsala, Sweden. E-mail: axel.akerblom@ucr.uu.se.
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